SLC5A2 and type 2 diabetes mellitus: We identified that SGLT2 inhibitor kidney outcome trial participants differed substantially from the real-world English primary care CKD population; trial participants were younger, more likely to have a co-existing T2D and had more advanced kidney disease, with lower eGFR and higher levels of albuminuria, compared with the trial eligible and total CKD primary care populations.